MAKE DUPIXENT YOUR FIRST-CHOICE BIOLOGIC
Symptoms
1 YEAR improvement in sense of smell (UPSIT) and nasal congestion3,b,c
2 DAYS to improvement in nasal congestion (post hoc analysis; result is descriptive)4,d
3 DAYS to improvement in Loss of Smell (post hoc analysis; result is descriptive)4,e,f
FUTURE SURGERY AND/OR SCS USE
- 83% reduction in the need for sinus surgery through Week 52 (HR: 0.17 [95% CI: 0.07, 0.46])2
- 74% reduction in the need for SCS use through Week 52 (HR: 0.26 [95% CI: 0.18, 0.38])2
Individually, SCS reduction and need for sino-nasal surgery were not multiplicity-adjusted endpoints.
QUALITY OF LIFE
- 35% improvement at Week 4
vs 14% with placebo3,h
- 58% improvement at Week 52 vs 14% with placebo (P<0.0001)3,i
Week 24 (SINUS-52): 51% improvement in NC score with DUPIXENT (pooled arms) vs 15% improvement with placebo; LSM difference vs placebo -0.87 (95% CI: -1.03, -0.71) (coprimary endpoint).2,3
Week 24 (SINUS-24): -1.34 improvement in NC score with DUPIXENT vs -0.45 improvement with placebo; LSM difference vs placebo -0.89 (95% CI: -1.07,-0.71) (coprimary endpoint).2
bWeek 52 in SINUS-52 (other secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): 10.30 (95% CI: 8.50, 12.10) (9.53 from a baseline score of 13.46 vs -0.77 from a baseline score of 13.78, respectively).3
cWeek 52 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -0.98 (95% CI: -1.17, -0.79) (-1.35 from a baseline score of 2.48 vs -0.37 from a baseline score of 2.38, respectively).3
dLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.13, -0.01).4,5
eLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.12, -0.02). Patient-reported Loss of Smell score.4,5
fWeek 24 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295) and placebo + INCS (n=153): -0.98 (95% CI: -1.15, -0.81).2
gThe SNOT-22 score is calculated from a patient questionnaire where 22 symptoms are rated from 0 (“no problem”) to 5 (“as bad is it can be”) based on the severity and frequency of each particular item.2,3
hWeek 4 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) vs placebo + INCS (n=295, pooled arms): -10.57 (95% CI: -14.47, -6.66) (-18.97 from a baseline score of 50.16 vs -8.40 from a baseline score of 53.48, respectively).3
iWeek 52 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) vs placebo + INCS (n=153): -20.96 (95% CI: -25.03, -16.89) (-29.84 from a baseline score of 50.16 vs -8.88 from a baseline score of 53.48, respectively).3
Nasal congestion/obstruction (NC) score (range 0 to 3): reduced score indicates improvement.
CI, confidence interval; HR, hazard ratio; INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks; SCS, systemic corticosteroid; SNOT-22, 22-item Sino-Nasal Outcome Test; UPSIT, University of Pennsylvania Smell Identification Test.
Unique
Mechanism
of
Action (MOA)
Only DUPIXENT targets both IL‑4
and IL‑13 signaling, two of the key
drivers of local and systemic
type 2 inflammation.2,6,7,a
aThe mechanism of dupilumab action has not been
definitively established.2
Multiple Administration
Options
Work with your patients to decide
how to administer DUPIXENT:
either administer at home or
administer in the office.2
A patient may self-inject DUPIXENT—or a caregiver may
administer DUPIXENT—after training has been provided
by a healthcare provider on proper subcutaneous
injection technique using the pre-filled syringe or pre-
filled pen.2
Safety
Data
View safety data across
clinical trials.

Support can make all the difference. DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.
Check Formulary Status in Your Area
See the coverage status for DUPIXENT, prior authorization, and step edit information by ZIP code.